1.Date of occurrence of the change:2022/06/27
2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor):Natural-person director, institutional director and independent director.
3.Title and name of the previous position holder:
Director Michael Chang, Representative of Yi Tai Investment Co., Ltd.
Director Tamon Tseng, Representative of Yi Tai Investment Co., Ltd.
Director Yun Yen, Representative of Sheng Cheng Investment Co., Ltd.
Director Frank Chen, Representative of Sheng Cheng Investment Co., Ltd.
Independent Director Jerry Fong
Independent Director Taychang Wang
Independent Director Howard Lee
4.Resume of the previous position holder:
Director Michael Chang, Representative of Yi Tai Investment Co., Ltd / Chairman of the Board and CEO, OBI Pharma Inc.
Director Tamon Tseng, Representative of Yi Tai Investment Co., Ltd / Special Assistant to Legal Division, Ruentex Group
Director Yun Yen, Representative of Sheng Cheng Investment Co., Ltd./ Chairman of the Board, Tanvex BioPharma, Inc
Director Frank Chen, Representative of Sheng Cheng Investment Co., Ltd./ Vice President, Investment Management Department and Special Assistant to President, Ruentex Group
Independent Director Jerry Fong/ Dean of the Graduate Institute of Technology, Innovation and Intellectual Property Management, National ChengChi University
Independent Director Taychang Wang/ Accounting Professor, National Taiwan University
Independent Director Howard Lee / Chairman of the Board, TAHO Pharmaceuticals Ltd.
5.Title and name of the new position holder:
Director Michael Chang
Director Tamon Tseng, Representative of Yi Tai Investment Co., Ltd.
Director Yun Yen, Representative of Sheng Cheng Investment Co., Ltd.
Director Frank Chen, Representative of Sheng Cheng Investment Co., Ltd.
Independent Director Howard Lee
Independent Director Ming-Chin Chen
Independent Director Chin-Ting Chiu
6.Resume of the new position holder:
Director Michael Chang / Chairman of the Board and CEO, OBI Pharma Inc.
Director Tamon Tseng, Representative of Yi Tai Investment Co., Ltd / Special Assistant to Legal Division, Ruentex Group
Director Yun Yen, Representative of Sheng Cheng Investment Co., Ltd./ Chairman of the Board, Tanvex BioPharma, Inc
Director Frank Chen, Representative of Sheng Cheng Investment Co., Ltd./ Vice President, Investment Management Department and Special Assistant to President, Ruentex Group
Independent Director Howard Lee / Chairman of the Board, TAHO Pharmaceuticals Ltd.
Independent Director Ming-Chin Chen / Accounting Professor, National Chengchi University
Independent Director Chin-Ting Chiu / Member of Mediation Committee, Securities and Futures Investors Protection Center
7.Circumstances of change (Please enter “resignation”, “dismissal”, “term expired”, “death” or “new appointment”):Term expired
8.Reason for the change:Re-election due to term expired.
9.Number of shares held by the new position holder when elected:
Director Michael Chang / 3,872,692 shares
Director Tamon Tseng, Representative of Yi Tai Investment Co., Ltd./ 25,765,032 shares
Director Yun Yen, Representative of Sheng Cheng Investment Co., Ltd./ 3,254,218 shares
Director Frank Chen, Representative of Sheng Cheng Investment Co., Ltd./ 3,254,218 shares
Independent Director Howard Lee / 0 shares
Independent Director Ming-Chin Chen / 0 shares
Independent Director Chin-Ting Chiu / 0 shares
10.Original term (from __________ to __________):2019/06/27 to 2022/06/26
11.Effective date of the new appointment:2022/06/27
12.Turnover rate of directors of the same term:Not applicable.
13.Turnover rate of independent directors of the same term:Not applicable.
14.Turnover rate of supervisors of the same term:Not applicable.
15.Change in one-third or more of directors (Please enter “Yes” or “No”):Yes
16.Any other matters that need to be specified:None